109 related articles for article (PubMed ID: 7471126)
1. Phase II trial of Baker's antifol in metastatic renal cell carcinoma: a Southwest Oncology Group Study.
Bukowski RM; LoBuglio A; McCracken J; Pugh R
Cancer Treat Rep; 1980; 64(12):1387-8. PubMed ID: 7471126
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of Baker's antifol in metastatic sarcoma.
Thigpen JT; O'Bryan RM; Benjamin RS; Coltman CA
Cancer Treat Rep; 1977 Nov; 61(8):1485-7. PubMed ID: 922752
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study with Baker's Antifol in solid tumors.
Rodriguez V; Richman SP; Benjamin RS; Burgess MA; Murphy WK; Valdivieso M; Banner RL; Gutterman JU; Bodey GP; Freireich EJ
Cancer Res; 1977 Apr; 37(4):980-3. PubMed ID: 139205
[TBL] [Abstract][Full Text] [Related]
4. Studies of Baker's antifol, methotrexate, and razoxane in advanced gastric cancer: A Gastrointestinal Tumor Study Group Report.
Bruckner HW; Lokich JJ; Stablein DM
Cancer Treat Rep; 1982 Sep; 66(9):1713-7. PubMed ID: 7116348
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of Baker's antifol (triazinate, TZT, NSC-139,105) in advanced squamous cell carcinoma of cervix.
Arseneau JC; Bundy B; Dolan T; Homesley H; DiSaia PJ
Am J Clin Oncol; 1982 Feb; 5(1):61-4. PubMed ID: 6211087
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of Baker's antifol in patients with recurrent or inoperable head and neck cancer.
Krasnow S; Green M; Perry DJ; Eisenberger MA; Johnston-Early A; Muggia F; Cohen MH
Cancer Treat Rep; 1986 Aug; 70(8):1039-40. PubMed ID: 3524834
[No Abstract] [Full Text] [Related]
7. Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma.
Fuks JZ; Van Echo DA; Aisner J; Mitchell EP; Woolley PV; Wiernik PH
Cancer Clin Trials; 1981; 4(4):411-4. PubMed ID: 7318123
[TBL] [Abstract][Full Text] [Related]
8. Baker's antifol in combination with 5-fluorouracil and methyl-CCNU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group Study (Protocol 7764).
Shaw MT; Bonnet JD; Wilson H; Heilbrun LK
Cancer Treat Rep; 1980; 64(2-3):247-50. PubMed ID: 7407758
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of Baker's antifol in advanced colorectal cancer.
Padilla F; Correa J; Buroker T; Vaitkevicius VK
Cancer Treat Rep; 1978 Apr; 62(4):553-4. PubMed ID: 350391
[No Abstract] [Full Text] [Related]
10. Phase I--II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma.
Todd RF; Garnick MB; Canellos GP; Richie JP; Gittes RF; Mayer RJ; Skarin AT
Cancer Treat Rep; 1981; 65(1-2):17-20. PubMed ID: 7226167
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
Van Veldhuizen PJ; Faulkner JR; Lara PN; Gumerlock PH; Goodwin JW; Dakhil SR; Gross HM; Flanigan RC; Crawford ED;
Cancer Chemother Pharmacol; 2005 Jul; 56(1):39-45. PubMed ID: 15791454
[TBL] [Abstract][Full Text] [Related]
12. Baker's antifol in children with therapy-resistant solid tumors: a Southwest Oncology Group Study.
Nitschke R; Morgan SK; Land VJ
Cancer Treat Rep; 1981; 65(7-8):725-7. PubMed ID: 7248990
[No Abstract] [Full Text] [Related]
13. Phase II trial of dianhydrogalactitol in advanced renal cell carcinoma: a Southwest Oncology Group study.
Ratanatharathorn V; Baker LH; Balducci L; Talley RW; Hoogstraten B
Cancer Treat Rep; 1982 May; 66(5):1231-2. PubMed ID: 7083224
[No Abstract] [Full Text] [Related]
14. Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
Taylor SA; Von Hoff DD; Baker LH; Balcerzak SP
Cancer Treat Rep; 1984 Jun; 68(6):919-20. PubMed ID: 6733708
[No Abstract] [Full Text] [Related]
15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED
Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
Ajani JA; Ilson DH; Kelsen DP
Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study.
Look KY; Blessing JA; Valea FA; McGehee R; Manetta A; Webster KD; Andersen WA
Gynecol Oncol; 1997 Dec; 67(3):255-8. PubMed ID: 9441772
[TBL] [Abstract][Full Text] [Related]
19. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M
Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Davis NB; Taber DA; Ansari RH; Ryan CW; George C; Vokes EE; Vogelzang NJ; Stadler WM
J Clin Oncol; 2004 Jan; 22(1):115-9. PubMed ID: 14701773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
